과제정보
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (2021-R1F1A1045544, 2021-R1A4A1031574) and The National Natural Science Foundation of China (No. 82100413).
참고문헌
- Goette A, Lendeckel U. Atrial cardiomyopathy: pathophysiology and clinical consequences. Cells. 2021;10:2605.
- Sagris M, Vardas EP, Theofilis P, Antonopoulos AS, Oikonomou E, Tousoulis D. Atrial fibrillation: pathogenesis, predisposing factors, and genetics. Int J Mol Sci. 2021;23:6.
- Black N, D'Souza A, Wang Y, Piggins H, Dobrzynski H, Morris G, Boyett MR. Circadian rhythm of cardiac electrophysiology, arrhythmogenesis, and the underlying mechanisms. Heart Rhythm. 2019;16:298-307. https://doi.org/10.1016/j.hrthm.2018.08.026
- Schmitt N, Grunnet M, Olesen SP. Cardiac potassium channel subtypes: new roles in repolarization and arrhythmia. Physiol Rev. 2014;94:609-653. https://doi.org/10.1152/physrev.00022.2013
- Zhang Q, Chen J, Qin Y, Wang J, Zhou L. Mutations in voltagegated L-type calcium channel: implications in cardiac arrhythmia. Channels (Austin). 2018;12:201-218. https://doi.org/10.1080/19336950.2018.1499368
- Vaughan Williams EM. Classification of antidysrhythmic drugs. Pharmacol Ther B. 1975;1:115-138.
- Antonaccio MJ, Gomoll AW, Byrne JE. Encainide. Cardiovasc Drugs Ther. 1989;3:691-710. https://doi.org/10.1007/BF01857621
- Luderitz B, Mletzko R, Jung W, Manz M. Combination of antiarrhythmic drugs. J Cardiovasc Pharmacol. 1991;17 Suppl 6:S48-S52. https://doi.org/10.1097/00005344-199117041-00011
- Soyka LF. Safety of encainide for the treatment of ventricular arrhythmias. Am J Cardiol. 1986;58:96C-103C. https://doi.org/10.1016/0002-9149(86)90111-6
- Li H, Zhuang W, Xiong T, Park WS, Zhang S, Zha Y, Yao J, Wang F, Yang Y, Chen Y, Cai L, Ling L, Yu D, Liang J. Nrf2 deficiency attenuates atherosclerosis by reducing LOX-1-mediated proliferation and migration of vascular smooth muscle cells. Atherosclerosis. 2022;347:1-16. https://doi.org/10.1016/j.atherosclerosis.2022.02.025
- Shi J, Yang Y, Cheng A, Xu G, He F. Metabolism of vascular smooth muscle cells in vascular diseases. Am J Physiol Heart Circ Physiol. 2020;319:H613-H631. https://doi.org/10.1152/ajpheart.00220.2020
- Zhang L, Wang Y, Wu G, Rao L, Wei Y, Yue H, Yuan T, Yang P, Xiong F, Zhang S, Zhou Q, Chen Z, Li J, Mo BW, Zhang H, Xiong W, Wang CY. Blockade of JAK2 protects mice against hypoxia-induced pulmonary arterial hypertension by repressing pulmonary arterial smooth muscle cell proliferation. Cell Prolif. 2020;53:e12742.
- Tykocki NR, Boerman EM, Jackson WF. Smooth muscle ion channels and regulation of vascular tone in resistance arteries and arterioles. Compr Physiol. 2017;7:485-581. https://doi.org/10.1002/cphy.c160011
- Dogan MF, Yildiz O, Arslan SO, Ulusoy KG. Potassium channels in vascular smooth muscle: a pathophysiological and pharmacological perspective. Fundam Clin Pharmacol. 2019;33:504-523. https://doi.org/10.1111/fcp.12461
- Ko EA, Han J, Jung ID, Park WS. Physiological roles of K+ channels in vascular smooth muscle cells. J Smooth Muscle Res. 2008;44:65-81. https://doi.org/10.1540/jsmr.44.65
- Bobi J, Garabito M, Solanes N, Cidad P, Ramos-Perez V, Ponce A, Rigol M, Freixa X, Perez-Martinez C, Perez de Prado A, Fernandez-Vazquez F, Sabate M, Borros S, Lopez-Lopez JR, Perez-Garcia MT, Roque M. Kv1.3 blockade inhibits proliferation of vascular smooth muscle cells in vitro and intimal hyperplasia in vivo. Transl Res. 2020;224:40-54. https://doi.org/10.1016/j.trsl.2020.06.002
- Jackson WF. KV1.3: a new therapeutic target to control vascular smooth muscle cell proliferation. Arterioscler Thromb Vasc Biol. 2010;30:1073-1074. https://doi.org/10.1161/ATVBAHA.110.206565
- An JR, Li H, Seo MS, Park WS. Inhibition of voltage-dependent K+ current in rabbit coronary arterial smooth muscle cells by the class Ic antiarrhythmic drug propafenone. Korean J Physiol Pharmacol. 2018;22:597-605. https://doi.org/10.4196/kjpp.2018.22.5.597
- An JR, Kim HW, Li H, Seo MS, Jung WK, Ha KS, Han ET, Hong SH, Firth AL, Choi IW, Park WS. Inhibition of the voltage-dependent K+ current by the class Ic antiarrhythmic drug flecainide in rabbit coronary arterial smooth muscle cells. Clin Exp Pharmacol Physiol. 2018;45:1286-1292. https://doi.org/10.1111/1440-1681.13015
- Li H, Zhuang W, Seo MS, An JR, Yang Y, Zha Y, Liang J, Xu ZX, Park WS. Inhibition of voltage-dependent K+ channels in rabbit coronary arterial smooth muscle cells by the class Ic antiarrhythmic agent lorcainide. Eur J Pharmacol. 2021;904:174158.
- Hasan R, Jaggar JH. KV channel trafficking and control of vascular tone. Microcirculation. 2018;25:10.1111/micc.12418.
- Lu Y, Hanna ST, Tang G, Wang R. Contributions of Kv1.2, Kv1.5 and Kv2.1 subunits to the native delayed rectifier K(+) current in rat mesenteric artery smooth muscle cells. Life Sci. 2002;71:1465-1473. https://doi.org/10.1016/S0024-3205(02)01922-7
- Jaillon P. Pharmacokinetics and metabolism of encainide. Cardiovasc Drugs Ther. 1990;4 Suppl 3:561-565. https://doi.org/10.1007/BF00357031